Ikarian Capital, LLC Immunovant, Inc. Call Options Transaction History

Ikarian Capital, LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$27.51 - $27.51 $13.7 Million - $13.7 Million	499,000 Added 49900.0%	500,000 $13.8 Million
Q2 2024 Aug 14, 2024	BUY	$25.1 - $31.61 $25,100 - $31,610	1,000 New	1,000 $26,000
Q4 2023 Feb 14, 2024	BUY	$31.31 - $44.19 $9.19 Million - $13 Million	293,470 Added 4059.06%	300,700 $12.7 Million
Q3 2023 Nov 14, 2023	SELL	$18.55 - $39.96 $5.92 Million - $12.7 Million	-318,970 Reduced 97.78%	7,230 $277,000
Q2 2023 Aug 14, 2023	BUY	$14.2 - $23.75 $2.36 Million - $3.94 Million	165,900 Added 103.49%	326,200 $6.19 Million
Q1 2023 May 15, 2023	BUY	$15.27 - $19.72 $2.05 Million - $2.64 Million	134,100 Added 511.83%	160,300 $2.49 Million
Q4 2022 Feb 14, 2023	BUY	$6.59 - $17.75 $172,658 - $465,050	26,200 New	26,200 $465,000
Q2 2021 Aug 16, 2021	BUY	$9.4 - $16.85 $360,020 - $645,355	38,300 Added 10.59%	400,000 $4.23 Million
Q1 2021 May 17, 2021	BUY	$13.08 - $49.6 $4.73 Million - $17.9 Million	361,700 New	361,700 $5.8 Million

212

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.